A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

NCT01724086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: TMC647055
DRUG: TMC435
DRUG: Ritonavir
DRUG: Ribavirin
DRUG: Pegylated interferon alpha-2a (PegIFN)
DRUG: GSK2336805

Sponsor

Janssen R&D Ireland